Anavex’s Rett Syndrome Candidate Wins Orphan Drug Designation

Anavex Life Sciences has landed orphan drug status for a drug candidate aimed at treating Rett syndrome.

Last week, the company said that it is moving forward with planned clinical trials for the drug, which secured the orphan drug designation due to the lack of available treatments for Rett syndrome.